$$\begin{array}{c|c}
R^1 & R^2 \\
 & R^5 \\
 & R^6 \\
 & R^7 \\
 & R^3 & R^8
\end{array}$$
(I')

a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof, wherein

 R^1 and R^2 are each independently selected from hydrogen; hydroxy; amino; $C_{1\text{-}6}$ alkyl; $C_{1\text{-}6}$ alkyloxy; $C_{1\text{-}6}$ alkylcarbonyl; $C_{1\text{-}6}$ alkyloxycarbonyl; $C_{1\text{-}6}$ alkyl)amino; mono- or di($C_{1\text{-}6}$ alkyl)aminocarbonyl; dihydro-2(3H)-furanone; $C_{1\text{-}6}$ alkyl substituted with one or two substituents each independently selected from amino, imino, aminocarbonyl, aminocarbonylamino, hydroxy, hydroxy $C_{1\text{-}6}$ alkyloxy, carboxyl, mono- or di($C_{1\text{-}6}$ alkyl)amino, $C_{1\text{-}6}$ alkyloxycarbonyl and thienyl; or

 R^1 and R^2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C_{1-6} alkyl)amino C_{1-4} alkylidene;

 R^3 is one of hydrogen, Ar^1 , C_{1-6} alkylcarbonyl, C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl, and C_{1-6} alkyl substituted with C_{1-6} alkyloxycarbonyl; and

R⁴, R⁵, R⁷ and R⁸ are each independently selected from hydrogen, hydroxy, halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; R⁶ is aminocarbonyl;

L is one of C₁₋₁₀alkyl; C₃₋₁₀alkenyl; C₃₋₁₀alkynyl; and C₃₋₇cycloalkyl; or

L is C₁₋₁₀alkyl substituted with one or two substituents independently selected from the group consisting of C₃₋₇cycloalkyl; indolyl or indolyl substituted with one, two, three or four substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, or C₁₋₆alkylcarbonyl; and phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, or C₁₋₆alkylcarbonyl; and, Ar¹ is phenyl, or phenyl substituted with one, two or three substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, nitro or trifluoromethyl.

21

2. (previously presented) A compound according to claim 1 wherein R¹ and R² are each independently selected from hydrogen, C¹-6alkyl, Ar¹ or mono- or di(C¹-6alkyl)aminocarbonyl; or R¹ and R² taken together may form pyrrolidinyl, piperidinyl or morpholinyl; R³ is hydrogen, C¹-6alkyl or Ar¹; and Ar¹ is phenyl, or phenyl substituted with one, two or three substituents each independently selected from halo, C¹-6alkyl, C¹-6alkyloxy, cyano, nitro or trifluoromethyl; and

L is a radical of formula

$$R^{c}$$
 R^{b}
 R^{a}
 R^{e}

wherein Alk is C₁₋₆alkanediyl;

Ra, Rb, Rc, Rd, Re, R4, R5, R7 and R8 are each independently selected from hydrogen, halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; or

Ra and Rb taken together may form a bivalent radical of formula

-CH=CH-NR9-

(a-1),

-NR9-CH=CH-

(a-2),

wherein R⁹ is hydrogen or C₁₋₄alkyl.

- 3. (previously presented) A compound according to claim 1 wherein L is C₃₋₁₀alkenyl or C₁₋₂alkyl substituted with one or two substituents independently selected from C₃₋₇cycloalkyl; indolyl or indolyl substituted with one, two, three or four substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, C₁₋₆alkylcarbonyl; phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, C₁₋₆alkylcarbonyl.
- 4. (previously presented) A compound according to claim 3 wherein L is 2,6-dichlorophenylmethyl.

- 6. (previously presented) A compound according to claim 4 wherein NR¹R² is other than amino.
- 11. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as claimed claim 1.

18 (previously presented) A method of treating a subject suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

19. (currently amended) A compound of formula (VII),

wherein

 R^1 -and R^2 are each independently selected from hydrogen; hydroxy; amino; C_{1-6} alkyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; Ar^1 ; mono- or di(C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkyl)aminocarbonyl; dihydro-2(3H)- furanone; C_{1-6} alkyl substituted with one or two substituents each independently selected from amino, imino, aminocarbonyl, aminocarbonylamino, hydroxy, hydroxy C_{1-6} alkyloxy, carboxyl, mono- or di(C_{1-6} alkyl)amino, C_{1-6} alkyloxycarbonyl and thienyl; or

 R^1 and R^2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or $di(C_{1-6}alkyl)aminoC_{1-4}alkylidene;$

 R^3 is one of hydrogen, Ar^1 , C_{1-6} alkylcarbonyl, C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl, and C_{1-6} alkyl substituted with C_{1-6} alkyloxycarbonyl; and

R⁴, R⁵, R⁷ and R⁸ are each independently selected from hydrogen, hydroxy, halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; R⁶ is aminocarbonyl;

W⁵ is halo;

L is one of C_{1-10} alkyl; C_{3-10} alkenyl; C_{3-10} alkynyl; and C_{3-7} cycloalkyl; or

L is C₁₋₁₀alkyl substituted with one or two substituents independently selected from the group consisting of C₃₋₇cycloalkyl; indolyl or indolyl substituted with one, two, three or four

substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, or C₁₋₆alkylcarbonyl; and phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, or C₁₋₆alkylcarbonyl; and, Ar¹ is phenyl, or phenyl substituted with one, two or three substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, nitro or trifluoromethyl.